AS

Aileen Stockburger

Next Science Limited | Non-Executive Director, Non-Executive Chairman
Mr Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He held dirctorships in Microbot Medical Inc. as Non Executive Director from last 3 years. He is Member of Risk, People & Culture Committee.

Company and Roles

Company
Title
Tenure
Since
NXS
Next Science Limited
  • Non-Executive Director
  • Non-Executive Chairman
5yrs, 9mthOct 2018

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
NXS
Next Science Limited
28/02/24569,638N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
NXS
Next Science Limited
01/11/23
Issued
524,801$0.420$220,416Placement
NXS
Next Science Limited
06/05/20
Issued
11,283$1.990$22,453Director remuneration
NXS
Next Science Limited
19/12/19
Issued
7,977$2.820$22,495Director remuneration
NXS
Next Science Limited
25/09/19
Issued
25,577$1.661$42,475Director remuneration.